Suppr超能文献

新型基于聚甘油脂肪酸酯的纳米粒用于醋酸生育酚的经皮递送。

Development of novel polyglycerol fatty acid ester-based nanoparticles for the dermal delivery of tocopherol acetate.

机构信息

Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.

Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.

出版信息

Int J Pharm. 2021 Jan 5;592:120004. doi: 10.1016/j.ijpharm.2020.120004. Epub 2020 Oct 27.

Abstract

The aim of this study was to develop and evaluate novel polyglycerol fatty acid ester (PGFE)-based nanoparticles (NPs) for the dermal delivery of tocopherol acetate (TA). TA-loaded PGFE-based NPs (PGFE-NPs) were prepared by mixing PGFE, soya phosphatidylcholine, dimyristoylphosphatidylglycerol, and TA with film using the film rehydration and extrusion method. The prepared formulations were analyzed by dynamic light scattering, small-angle X-ray diffraction and polarization microscopy. An in vitro skin accumulation test was performed with TA under occlusive and non-occlusive applications, using Yucatan micropig skin. The size range of the TA-loaded liposome and PGFE-NPs was 107-128 nm, and they were encapsulated in 1.6-2.3 mg/mL TA. All PGFE-NP formulations were negatively charged and stable for 2 weeks. Under occlusive applications, all formulations induced small amounts of TA accumulation in the epidermis but not in the dermis. However, under non-occlusive applications, some of PGFE-NP formulations enhanced TA accumulation in the epidermis. Furthermore, only the polyglycerol 4-laurate (PG4L)-based formulation induced dermal TA accumulation with the change in the formulation from a vesicular to bilayer stacked structure following water evaporation under non-occlusive applications. These results indicated that the novel TA-loaded PG4L formulation enabled the dermal delivery of TA in non-occlusive applications.

摘要

本研究旨在开发和评价新型聚甘油脂肪酸酯(PGFE)纳米粒(NPs)用于醋酸生育酚(TA)的经皮给药。TA 负载的 PGFE 基 NPs(PGFE-NPs)是通过将 PGFE、大豆卵磷脂、二肉豆蔻酰磷脂酰甘油和 TA 与薄膜混合,使用薄膜再水化和挤出方法制备的。用动态光散射、小角 X 射线衍射和偏光显微镜分析所制备的制剂。采用封闭和非封闭应用,用人 Yucatan 微型猪皮进行 TA 的体外皮肤累积试验。载有 TA 的脂质体和 PGFE-NPs 的粒径范围为 107-128nm,它们分别包裹在 1.6-2.3mg/mL 的 TA 中。所有 PGFE-NP 制剂均带负电荷且在 2 周内稳定。在封闭应用下,所有制剂均诱导 TA 少量积聚在表皮中,而不在真皮中。然而,在非封闭应用下,一些 PGFE-NP 制剂增强了 TA 在表皮中的积聚。此外,只有聚甘油 4-月桂酸酯(PG4L)基制剂在非封闭应用下诱导了皮肤中 TA 的积累,这是由于制剂中的水蒸发后从囊泡转变为双层堆叠结构。这些结果表明,新型 TA 负载的 PG4L 制剂能够实现非封闭应用下 TA 的经皮给药。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验